Share

Profile & Fundamentals

JD Health Profile & Fundamentals

Name: JD Health financial chart data preview
Creator: iPulse AI
License: https://ipulseai.com/terms

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables

Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Jump directly to any section

Company and Market Context

Company Profile & Ownership

JD Health International Inc., an investment holding company, engages in the operation of an online healthcare platform in the People's Republic of China. It provides online medical consultation, hospital or doctor referral, health check-ups, genetic testing, and beauty care services, as well as internet healthcare, health management, intelligent healthcare, advertising, and technical services. The company also offers home care services, including wound care, blood tests and diagnostics, post-operative care, and medical escort; online medical insurance payment services; and smart healthcare and digital health solutions. In addition, it provides online marketing services to advertisers; and online shopping and hospital services. Further, the company offers smart monitoring and respiratory therapy devices; senior-oriented medical devices; home medical device set-up and support services, including blood glucose meters and oxygen generators; and rapid testing products. Additionally, it provides traditional Chinese medicine (TCM) wellness and professional orthopedic services, as well as operates offline examination and polyclinic centers that offers convenient and professional healthcare services. The company offers pharmaceutical and healthcare products through direct sales, and online marketplace and on-demand retail businesses. It serves pharmaceutical and healthcare product companies. JD Health International Inc. was founded in 2014 and is headquartered in Beijing, the People's Republic of China. JD Health International Inc. is a subsidiary of JD Jiankang Limited.

Company profile record

Jd Health International Inc

Common Stock · Health Care · Health Care Facilities

Official website

Company

Company / asset: Jd Health International Inc
Security type: Common Stock
Sector: Health Care
Industry: Health Care Facilities
HQ: 🇨🇳 China
Head office: Jingdong Headquarters, Beijing, China, 101111

Leadership & scale

Chief executive: Mr. Cao Dong
CEO year born: 1977
Full-time employees: 6K
Fiscal year end: December

Fundamentals snapshot

Updated 2026-09-09

Market Cap: HKD 116.3B
P/E: 9.7x
Revenue (Q2 26): CNY 40.3B
Profit (Q2 26): CNY 3.4B
Dividend Yield: --
Revenue (FY 25): CNY 73.4B
Shares in public float: 1B
Insider ownership: 68.2%

Reporting & identifiers

Symbol: 6618.HKEX
Listing: 🇭🇰 Hong Kong | Dividend Tax: 0%
Ticker Currency: HKD
Income Statement Currency: CNY
Balance Sheet Currency: CNY
Cash Flow Currency: CNY
EPS Currency: CNY
Contract Type: SPOT
ISIN: KYG5074A1004
Asset ID: equity_21381989-d6f7-5f5e-a316-4ab9600ebdb7

Ownership

Shares Outstanding

Shares outstanding

Annual reported shares outstanding. Values in shares.

Earnings, Profitability & Valuation

Earnings & Revenue

AI Review

The company has successfully transitioned from a loss-making business into a highly profitable cash-generating machine. In 2025, revenues grew steadily to 73.4 billion CNY, and net income rose to 5.38 billion CNY. More importantly, the company generated a spectacular 9.75 billion CNY in free cash flow, showing that it actually brings in far more cash than its reported profits suggest. Analysts agree that this strong cash flow is highly secure due to the guaranteed demand for healthcare from China's aging population. However, there is some disagreement on future growth rates. Some expect double-digit growth to continue as new partnerships scale, while others caution that growth might slow down slightly as the business matures. Overall, the financial trend is highly positive, offering a safe haven in a tough global economy.

Revenue, Net Income, and Free Cash Flow

Revenue
Free cash flow
Net income

Annual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.

Valuation

Historical P/E Ratio

Published P/E

Published valuation snapshots. Trailing four-quarter earnings where available; annual earnings otherwise. Non-positive earnings are omitted. Values in times earnings.

Profitability & Margins

AI Review

The company's profit margins are on a steady upward path. Gross margins have stabilized at a healthy 24.8%, and net margins have reached 7.32%. This improvement is driven by a shift in the business mix, as the company sells more high-margin digital health services and uses AI to handle patient questions, which lowers its labor costs. Analysts agree that these margins are structurally stronger than traditional physical pharmacies. However, there is a clear clash of opinions regarding the future ceiling for these margins. Some believe that AI automation will drive margins much higher, while others warn that government price controls on medicines and intense competition from rival platforms will cap how profitable the company can ultimately become. Despite these concerns, the overall margin outlook remains highly supportive of the company's value.

Profitability Margins

Gross margin
Operating margin
Net margin
Free cash flow margin

Annual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.

Sign in to check access View Base plan

Paywalled preview begins: Reported Data Tables — chart preview

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Reported Data Tables — chart preview

The following tables contain the same values as the financial charts above. Monetary values are USD; margins are percentages. Missing inputs are not estimated. Use is subject to the iPulse AI Terms of Service and applicable source rights.

Source: eodhd. Statement snapshots with chart transformations and ratios calculated by iPulse AI. Snapshot retrieved 2026-09-10.

Annual earnings and profitability
Period end	Revenue	Free cash flow	Net income	Gross margin	Operating margin	Net margin	Free cash flow margin
2017-12-31	853,015,053.76	4,223,195.08	27,424,577.57	24.86	4.62	3.22	0.5
2018-12-31	1,187,362,936.05	26,861,918.6	31,239,389.53	24.23	3.76	2.63	2.26
2019-12-31	1,557,778,735.63	58,086,781.61	-139,627,155.17	25.94	3.98	-8.96	3.73
2020-12-31	2,968,233,996.94	564,129,402.76	-2,639,259,264.93	25.37	1.81	-88.92	19.01
2021-12-31	4,824,255,817.61	460,457,389.94	-168,790,408.81	23.46	-4.58	-3.5	9.54
2022-12-31	6,773,355,072.46	849,998,405.8	55,087,681.16	21.16	-0.31	0.81	12.55
2023-12-31	6,854,025,736.24	638,795,070.42	274,243,405.89	22.17	1.31	4	9.32
2024-12-31	7,485,184,169.88	551,610,296.01	535,629,858.43	22.88	2	7.16	7.37
2025-12-31	10,506,650,500.72	1,395,239,546.35	769,013,590.84	24.78	5.17	7.32	13.28

Published valuation snapshots
Period end	P/E (times earnings)	Earnings basis
2025-12-31	17.65	Trailing four quarters
2024-12-31	13.89	Trailing four quarters
2022-12-31	522.23	Annual net income

Shares outstanding — chart values
Reporting date	Shares outstanding
2017-01-01	3,127,082,100
2018-01-01	3,127,082,100
2019-01-01	2,638,167,900
2020-01-01	2,267,793,700
2021-01-01	3,098,101,000
2022-01-01	3,149,005,000
2023-01-01	3,165,458,000
2024-01-01	3,164,855,000
2025-01-01	3,202,719,000
2026-01-01	3,204,362,000

End of the paywalled preview

The excerpt from Reported Data Tables — chart preview to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Earnings, Profitability & Valuation
- Complete profitability ratios
- EPS history and estimate comparisons
- Execution vs expectations
- Annual and quarterly financial views
Capital Expenditure & R&D
- Capital allocation AI review
- Annual capital expenditure
- Investment intensity trends
- Capex and R&D intensity indicators
Balance Sheet
- Balance sheet AI review
- Assets, debt and equity
- Capital structure
- Liquidity and leverage
- Retained earnings
Dividends & Actions
- Cash dividends paid
- Dividend indicators
- Buybacks and issuance
- Combined shareholder returns
- Available corporate actions

Explore complete public research examples

These public assets show the complete asset profiles, fundamental datasets and analysis. Their findings concern those assets, not this report.